Immunome announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy targeting fibroblast activation protein. Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research, AACR, Annual Meeting 2024, which is taking place April 5-10 in San Diego, California. “FAP is an attractive target for cancer therapy, but trials with first-generation FAP-RLTs have produced modest clinical responses, indicating the need for novel agents with improved therapeutic properties,” commented Dr. Higgins. “We believe IM-3050 has best-in-class potential and look forward to sharing preclinical data for the program at AACR.” Immunome expects to submit an Investigational New Drug application to the U.S. Food & Drug Administration for IM-3050 in the first quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome files to sell 2.23M shares of common stock for holders
- Immunome files to sell 2.18M shares of common stock for holders
- Immunome price target raised to $33 from $27 at Wedbush
- Immunome’s Strategic Acquisition to Revolutionize Cancer Treatment
- Ayala Pharmaceuticals completes sale of AL102 to Immunome
